Understand · Treat · Recover
Metastatic Gastric and GEJ Cancer
Metastatic disease has spread beyond the original region. Treatment usually aims to prolong life, control cancer and preserve quality of life.
For patients, families and caregivers worldwide. Approvals, access and care pathways vary by country. Evidence checked 21 October 2026.
This information is provided for general educational purposes and does not replace individualized medical advice. Diagnosis and treatment decisions should be made with a qualified healthcare team.
Chapter 14 of 20
Where cancer can spread
Common sites include the peritoneum, liver, distant lymph nodes and lungs; other organs can also be involved. Ascites is fluid in the abdomen and may require testing or drainage. A metastatic deposit is treated according to the original cancer type, not automatically as a new liver or lung cancer. Confirming the histology and treatment history remains important.
The chemotherapy foundation
A fluoropyrimidine such as 5-FU or capecitabine with a platinum drug, often oxaliplatin, is a common first-line backbone. FOLFOX and CAPOX are examples. Kidney function, swallowing, neuropathy, frailty and treatment logistics influence selection. Less intensive treatment or symptom-focused care may be better for a person with very poor functional status. Tablets are not necessarily milder than infusions.
Biomarkers change the first-line discussion
| Finding | A treatment discussion it can support |
|---|---|
| HER2-positive | Trastuzumab plus chemotherapy; pembrolizumab addition for eligible PD-L1-positive disease under the relevant label. |
| HER2-negative, PD-L1-positive | A checkpoint inhibitor plus chemotherapy when appropriate; magnitude of benefit varies with CPS. |
| MSI-high / dMMR | Strong rationale to consider an immunotherapy-based approach with setting-specific eligibility. |
| HER2-negative, CLDN18.2-positive | Zolbetuximab plus fluoropyrimidine/platinum chemotherapy where approved. |
| No qualifying marker or immunotherapy unsuitable | Chemotherapy alone remains a reasonable option. |
A newer HER2 option in some countries
In August 2026, the US FDA approved first-line zanidatamab with chemotherapy and tislelizumab for HER2 IHC 3+ or IHC 2+/ISH-positive advanced gastroesophageal adenocarcinoma. Zanidatamab with chemotherapy without tislelizumab has a narrower IHC 3+ indication. Availability and approval elsewhere must be checked.
Avoid treating markers in isolation
Some tumours have overlapping PD-L1 and CLDN18.2 positivity. There is no automatic instruction to combine every active antibody. The team weighs disease burden, likely benefit, toxicity, coexisting autoimmune disease or transplant history, access and the evidence for each combination. An older approval announcement may differ from the current label; eligibility must be checked in the treating country.
Measuring benefit and protecting quality of life
Response assessment combines scans with symptoms, weight, examination and laboratory tests. Discuss the reassessment interval and what counts as useful benefit. After initial control, selected drugs may be reduced or stopped because of cumulative toxicity while a maintenance strategy continues. Surgery to remove the primary is not routinely curative in widespread disease; local procedures may be appropriate for bleeding or obstruction. Trials and early palliative care should be considered alongside standard therapy.
Key takeaways
Build the first-line plan from biomarkers, functional fitness and the person’s priorities.
Frequently asked questions
Can stage IV disease be treated?
Yes. Many patients can benefit from systemic therapy and symptom-directed care.
Does treatment always mean cure?
No. The usual intent in metastatic disease is control and longer, better life.
Must everyone receive immunotherapy?
No. Biomarkers, contraindications and local eligibility affect the balance of benefit and harm.
Can the primary tumour be removed to cure metastatic disease?
Not routinely. Highly selected approaches need specialist evaluation, often within research.
Does a marker level alone prove progression?
No. Markers must be interpreted with imaging and clinical findings.
Can supportive care be the main plan?
Yes, when treatment burdens outweigh likely benefit or that best matches the person’s goals.
References and further reading
- ESMO Open · Pan-Asian adapted guideline (2024); regional context supplemented by newer evidence
- CheckMate 649 · Randomized trial, Lancet (2021)
- KEYNOTE-859 · Randomized trial, Lancet Oncology (2023)
- FDA · Pembrolizumab approval package including gastric indications (May 2026)
- FDA · Zolbetuximab / SPOTLIGHT and GLOW (2024)
- NCI · Palliative care in cancer
- FDA · Zanidatamab / tislelizumab, HERIZON-GEA-01, 25 August 2026
- DailyMed · Current nivolumab prescribing information